Overview
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. All patients enrolled must have a mitogen-activated protein kinase (MAPK) activating mutation to be deemed eligible for trial participation. Each disease-based basket will open to enrollment in two-stages. The opening of stage two will be dependent on the observed responses in the patients enrolled in the first stage.
Description
This is an open-label, multicenter, phase II basket study of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring rat sarcoma virus (RAS), a member of the rapidly accelerated fibrosarcoma (non-V600 BRAF), extracellular signal-regulated kinase (ERK), or mitogen-activated protein kinase (MEK) mutations. The trial will have five baskets based on disease primary as listed below.
Basket 1: Cholangiocarcinoma including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, or extrahepatic cholangiocarcinoma;
Basket 2: Pancreatic adenocarcinoma;
Basket 3: Colorectal adenocarcinoma;
Basket 4: Esophageal adenocarcinoma, esophageal squamous cell carcinoma, or gastroesophageal junction (GEJ) adenocarcinoma;
Basket 5: Gastric adenocarcinoma.
While the overall trial is a basket design, each basket will operate as a Simon two-stage design and therefore, will open to enrollment in two-stages.
Total enrollment for Stage 1 is targeted at approximately 65 patients with 13 patients per group. Additional patients may be enrolled as appropriate.
Total enrollment for Stage 2 is targeted to approximately 150 patients with up to 30 patients per group. Additional patients may be enrolled as appropriate.
Eligibility
Inclusion Criteria:
- Male or female patient aged ≥ 18 years.
- Histologically confirmed esophageal adenocarcinoma, esophageal squamous cell carcinoma, GEJ adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, extrahepatic cholangiocarcinoma, or colorectal adenocarcinoma harboring a MAPK-mutated GI malignancy: KRAS, NRAS, HRAS, BRAF non-V600, MEK 1/2 (MAP2K1/2), or ERK 1/2 (MAPK3/1).
- Progression on or during standard lines of therapy:
- Patients with intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, or extrahepatic cholangiocarcinoma must have progressed during or after receiving a first-line regimen of gemcitabine/cisplatin unless deemed ineligible by the treating investigator to receive chemotherapy-based regimens due to prior comorbidities.
- Patients with pancreatic adenocarcinoma must have progressed during or after first-line therapy of FOLFIRINOX/ mFOLFIRINOX, gemcitabine/nab-paclitaxel unless deemed ineligible by the treating investigator to receive chemotherapy-based regimens due to prior comorbidities.
- Patients with colorectal adenocarcinoma must have progressed during or after their first two lines of therapy, including FOLFOX ± Avastin and FOLFIRI ± Avastin, unless deemed ineligible by the treating investigator to receive chemotherapy-based regimens due to prior comorbidities.
- Patients with esophageal adenocarcinoma, esophageal squamous cell carcinoma, GEJ adenocarcinoma, or gastric adenocarcinoma must have progressed during or after their first two lines of therapy.
- Acceptable first-line regimens: FOLFOX, 5-FU/Cisplatin, FOLFIRI, Paclitaxel/Cisplatin or Carboplatin, Docetaxel/Cisplatin, DCF (or modifications thereof), or ECF (or modifications thereof) unless deemed ineligible by the treating investigator to receive chemotherapy-based regimens due to prior comorbidities.
- Acceptable second-line regimens: Ramucirumab/Paclitaxel, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipiracil, or FOLFIRI, unless deemed ineligible by the treating investigator to receive chemotherapy-based regimens due to prior comorbidities.
- Patients with deficient MisMatch Repair/High levels of MicroSatellite Instability (dMMR/MSI-H) tumors must have progressed during or after pembrolizumab.
- Measurable disease by RECIST 1.1 criteria by computed tomography (CT) or magnetic
resonance imaging (MRI).
- Willing to provide a biopsy at the time points indicated on the Schedule of Activities.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
- Adequate organ function as defined as:
- Hematologic
-
- Absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 100,000/mm3
- Hemoglobin ≥ 9 g/dL
- Hepatic
-
- Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
- Asparate animotransferace /Alanine aminotransferase (AST(SGOT)/ALT(SGPT)) ≤ 3 × institutional ULN
- Patients with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
- Renal
-
- Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula:
- Males:
(140-age) × weight [kg] / serum creatinine [mgdL] × 72
- Females:
((140-age) × weight [kg] / serum creatinine [mgdL] × 72)×0.85
8. For female patients: Negative serum pregnancy test within 72 hours prior to first dose
of study drugs for women of childbearing potential. The following definitions apply:
- Women of childbearing potential, defined as a sexually mature woman:
- Has not been naturally post-menopausal for at least 12 consecutive months (i.e.,
who has had menses anytime in the preceding 12 consecutive months).
- Has not undergone menopause, surgical sterilization (bilateral oophorectomy or
hysterectomy).
- Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
- Women not of childbearing potential:
- Amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, if any.
- Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy
or hysterectomy).
9. Male and female patients of childbearing potential agree to use highly effective
contraception throughout the study and at least 90 days after the last study treatment
administration.
10. Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior
cancer therapy, unless considered clinically not significant by the treating
investigator.
11. Able to provide informed consent and willing to sign an approved consent form that
conforms to federal and institutional guidelines.
Exclusion Criteria:
1. Received systemic antineoplastic therapy (including unconjugated therapeutic
antibodies and toxin immunoconjugates) or any investigational therapy ≤ 14 days or
within five half-lives prior to starting study treatment, whichever is shorter.
2. Received radiotherapy ≤ 14 days prior to the first dose of study treatment.
Note: Localized radiation therapy for the treatment of symptomatic bone metastasis is
allowed during that timeframe.
3. Undergone major surgery ≤ 3 weeks prior to starting study drug or who have not fully
recovered from major surgery.
4. The diagnosis of another malignancy within ≤ 3 years before study enrollment, except
for those considered to be adequately treated with no evidence of disease or symptoms
and/or will not require therapy during the study duration (i.e., basal cell or
squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix,
or low-grade prostate cancer with Gleason Score ≤ 6).
5. Known uncontrolled brain metastases or cranial epidural disease.
Note: Patients with stable brain metastases either treated or being treated with a
stable dose of steroids (<20 mg of prednisone daily or equivalent) or anticonvulsants,
with no dose change within 4 weeks before the first study drug dose, and no
anticipated dose change, are eligible. In the event of steroid taper post-radiation
therapy, taper must be complete within 2 weeks before Baseline.
6. History or current evidence of central serous retinopathy (CSR) or retinal vein
occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular
hypertension, history of hyperviscosity).
7. Current evidence of uncontrolled, significant intercurrent illness including, but not
limited to, the following conditions:
Cardiovascular disorders:
- Congestive heart failure New York Heart Association Class 3 or 4, unstable angina
pectoris, serious cardiac arrhythmias.
- Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI),
or other ischemic events, or thromboembolic event (eg, deep venous thrombosis,
pulmonary embolism) within 3 months before the first dose.
- Duration of QT interval (QTc prolongation) defined as a QTcF > 500 ms.
- Known congenital long QT.
- Left ventricular ejection fraction < 50%.
History of seizures
Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative
disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
Any other condition that would, in the Investigator's judgment, contraindicate the
patient's participation in the clinical study due to safety concerns or compliance
with clinical study procedures (e.g., infection/inflammation, intestinal obstruction,
unable to swallow medication, [patients may not receive the drug through a feeding
tube], social/ psychological issues, etc.)
8. Prior stomach or duodenal resection that in the opinion of the Principal Investigator
and Medical Monitor would affect the breakdown and absorption of the study
medications. A patient with a feeding tube should also be excluded, as ulixertinib
capsules cannot be broken apart.
9. Known HIV infection with a detectable viral load within 6 months of the anticipated
start of treatment.
Note: Patients on effective antiretroviral therapy with an undetectable viral load
within 6 months of the anticipated start of treatment are eligible for this trial.
10. Active infection including tuberculosis (clinical evaluation that includes clinical
history, physical examination, radiographic findings, and tuberculosis (TB) testing in
line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg)
result), or hepatitis C.
Note: Patients with a past or resolved HBV infection (defined as the presence of
hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients
positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction
is negative for HCV RNA.
11. Medical, psychiatric, cognitive or other conditions that may compromise the patient's
ability to understand the patient information, give informed consent, comply with the
study protocol or complete the study.
12. Known prior severe hypersensitivity to investigational product (IP) or any component
in its formulations (NCI CTCAE v5.0 Grade ≥ 3).
13. Patients taking prohibited medications as described in protocol. A washout period of
prohibited medications for a period of at least 5 half-lives or as clinically
indicated should occur before the start of treatment.